Radiofrequency-Based Debridement vs. Mechanical Debridement for the Treatment of Articular Cartilage Lesions

Articular Cartilage Disorder of Knee Clinical Trial

Official title:

Evaluation of the Efficacy of Radiofrequency-Based Debridement vs. Mechanical Debridement for the Treatment of Articular Cartilage Lesions

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03678948
• Other study ID #: 2018H0244
• Status: Terminated
• Phase: N/A
• Start date: November 8, 2018
• Est. completion date: February 8, 2021

Study information

• Verified date: September 2021
• Source: Ohio State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the changes in clinical and imaging outcomes following arthroscopic treatment of chondral lesion(s) by Radiofrequency-Based debridement or Mechanical Debridement in subjects 18-50 years of age.

Description:

This is a non-inferiority, prospective, single blinded, randomized, single-center study design with enrollment of 82 randomized subjects (to assure 70 subjects complete the study). The sample size of 82 participants was calculated from a power analysis. The study was powered to detect at least a seven point change in KOOS pain score based on achieving 80% statistical power to detect a non-inferiority margin. Study duration will be until the last subject enrolled reaches 52 weeks post-operative.

The 82 randomized subjects will be randomized at a 1:1 ratio into the Werewolf Coblation wand treatment group or mechanical debridement treatment group. Subjects will be blinded to their treatment assignment until they complete all study visits. Upon withdraw from the study, termination from the study, or new or recurrent symptoms requiring a subsequent arthroscopy, the blinded assignment will be revealed to the subject.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: February 8, 2021
• Est. primary completion date: February 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Given written informed consent on the IRB approved consent form specific to the study, prior to study participation

• 18-50 years old

• Male or Female

• Suspected chondral damage in the following locations where debridement is indicated:

• Medial femoral condyle

• Lateral femoral condyle

• Trochlea

• Patella

• < 30% joint space narrowing as seen on x-ray (merchant view, AP and PA Rosenberg)

• 1 or more chondral lesion(s) as noted on MRI

Exclusion Criteria:

• Previous chondral treatment in the same compartment (prior debridement and lavage performed more than three months prior to baseline are acceptable)

• Focal chondral defect indicated for concomitant procedures (i.e., microfracture, ACI, MACI, OATs)

• Concomitant procedures that are not allowed:

• Lateral retinacular release

• Excision of osteophytes

• Subchondroplasty

• Manipulation under anesthesia

• ACL reconstruction

• Quad tendon repair

• Patellar tendon repair

• Patellar tendon debridement

• Multiligament reconstruction

• Pregnant and/or intending to become pregnant during this study period

Related Conditions & MeSH terms

• Articular Cartilage Disorder of Knee
• Cartilage Diseases

Intervention

Device:
• Radiofrequency-Based Debridement
In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
• Mechanical Debridement
Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement

Locations

Country	Name	City	State
United States	The Ohio State University Wexner Medical Center Jameson Crane Sports Medicine Institute	Columbus	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Christopher Kaeding	Smith & Nephew, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Knee and Osteoarthritis Outcome Scores (KOOS) activity subscale	The previous week is the time period considered when answering the questions. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.	change from baseline at week 52 post-op
Secondary	Visual Analogue Scale (VAS)	Using a ruler, the score is determined by mea-suring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.	change from baseline at week 52 post-op
Secondary	International Knee Documentation Committee (IKDC) subjective knee evaluation		change from baseline at week 52 post-op
Secondary	International Knee Documentation Committee (IKDC) objective knee		change from baseline at week 52 post-op
Secondary	Marx Activity Rating Scale (MARS)	MARS includes 4 items that assess the frequency of running, cutting, decelerating, and pivoting based on the subjects "healthiest and most active state in the past year." A higher score indicates more functional demand on the knee joint and potentially a higher risk of injury. Each item is scored on a 5-point ordinal scale ranging from 0 (less than 1 time in a month) to 4 (4 or more times in a week), and the total scale score is obtained by summing the individual items' scores (range, 0-16).	change from baseline at week 52 post-op
Secondary	Work Productivity and Activity Impairment (WPAI V2.0)	Asks about the effect of patient knee injury on their ability to work and perform normal daily activities	change from 1 week post op to 6 weeks post-op
Secondary	MRI	Baseline MRI will be compared to MRI at 52 weeks to evaluate knee morphology, cartilage signal, osteophytes, bone marrow edema, subarticular cysts, effusions and loose bodies. The international cartilage repair score will be used.	change from baseline at week 52 post-op